Literature DB >> 27860311

Single Heteroatom Substitutions in the Efavirenz Oxazinone Ring Impact Metabolism by CYP2B6.

Philip M Cox1, Namandjé N Bumpus1.   

Abstract

Previously, we observed that the oxazinone ring is important for cytochrome P450 2B6 (CYP2B6) activity toward efavirenz ((4S)-6-chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one), a CYP2B6 substrate used to treat HIV. To further understand the structural characteristics of efavirenz that render it a CYP2B6 substrate, we tested the importance of each heteroatom of the oxazinone ring. We assembled a panel of five analogues: 6-chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-2-methyl-4-(trifluoromethyl)-2H-3,1-benzoxazine (1), (4S)-6-chloro-4-[(1E)-2-cyclopropylethenyl]-3,4-dihydro-4-(trifluoromethyl)-2(1H)-quinazolinone (2), (4S)-6-chloro-4-(2-cyclopropylethynyl)-3,4-dihydro-4-(trifluoromethyl)-2(1H)-quinazolinone (3), 6-chloro-4-(cyclopropylethynyl)-3,4-dihydro-4-(trifluoromethyl)-2(1H)-quinolinone (4), and 6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-4H-benzo[d][1,3]dioxin-2-one (5). The metabolism of compounds 1-5 was investigated using human liver microsomes, individual P450s, and mass spectrometry or UV/Vis absorbance detection. Steady-state analysis of CYP2B6 metabolism of 1-5 showed KM values ranging from 0.3- to 3.9-fold different from that observed for efavirenz (KM : 3.6±1.7 μm). The lowest KM values, approximating 1 μm, were observed for the metabolism of 1, whereas the greatest KM value, 14±6.4 μm, was found for 4. Our work reveals that analogues with heteroatom changes in the oxazinone ring are still CYP2B6 substrates, although the changes in KM suggest altered substrate binding.
© 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cytochromes P450; drug metabolism; efavirenz; structure-activity relationships

Mesh:

Substances:

Year:  2016        PMID: 27860311      PMCID: PMC5155582          DOI: 10.1002/cmdc.201600519

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  26 in total

1.  The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Authors:  Bryan A Ward; J Christopher Gorski; David R Jones; Stephen D Hall; David A Flockhart; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

Review 2.  Pharmacogenetics of anti-HIV drugs.

Authors:  A Telenti; U M Zanger
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

3.  Further characterization of the expression in liver and catalytic activity of CYP2B6.

Authors:  S Ekins; M Vandenbranden; B J Ring; J S Gillespie; T J Yang; H V Gelboin; S A Wrighton
Journal:  J Pharmacol Exp Ther       Date:  1998-09       Impact factor: 4.030

4.  Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers.

Authors:  Stephanie R Faucette; Tong-Cun Zhang; Rick Moore; Tatsuya Sueyoshi; Curtis J Omiecinski; Edward L LeCluyse; Masahiko Negishi; Hongbing Wang
Journal:  J Pharmacol Exp Ther       Date:  2006-10-13       Impact factor: 4.030

5.  Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz.

Authors:  A E Mutlib; H Chen; G A Nemeth; J A Markwalder; S P Seitz; L S Gan; D D Christ
Journal:  Drug Metab Dispos       Date:  1999-11       Impact factor: 3.922

6.  Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.

Authors:  Haoming Zhang; Chitra Sridar; Cesar Kenaan; Hemali Amunugama; David P Ballou; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2011-06-09       Impact factor: 4.030

7.  Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism.

Authors:  Evan D Kharasch; Karen J Regina; Jane Blood; Christina Friedel
Journal:  Anesthesiology       Date:  2015-11       Impact factor: 7.892

8.  Quantitative structure-activity relationships within a homologous series of 7-alkoxyresorufins exhibiting activity towards CYP1A and CYP2B enzymes: molecular modelling studies on key members of the resorufin series with CYP2C5-derived models of human CYP1A1, CYP1A2, CYP2B6 and CYP3A4.

Authors:  David F V Lewis; Brian G Lake; M Dickins
Journal:  Xenobiotica       Date:  2004-06       Impact factor: 1.908

9.  The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects.

Authors:  Sarah C Sim; Magnus Ingelman-Sundberg
Journal:  Hum Genomics       Date:  2010-04       Impact factor: 4.639

10.  Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance.

Authors:  Ulrich M Zanger; Kathrin Klein
Journal:  Front Genet       Date:  2013-03-05       Impact factor: 4.599

View more
  4 in total

1.  Efavirenz and Efavirenz-like Compounds Activate Human, Murine, and Macaque Hepatic IRE1α-XBP1.

Authors:  Carley J S Heck; Allyson N Hamlin; Namandjé N Bumpus
Journal:  Mol Pharmacol       Date:  2018-11-15       Impact factor: 4.436

Review 2.  Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.

Authors:  Pan-Fen Wang; Alicia Neiner; Evan D Kharasch
Journal:  Drug Metab Dispos       Date:  2019-07-19       Impact factor: 3.922

3.  Crystal Structure of CYP2B6 in Complex with an Efavirenz Analog.

Authors:  Manish B Shah; Qinghai Zhang; James R Halpert
Journal:  Int J Mol Sci       Date:  2018-03-29       Impact factor: 5.923

4.  Electrochemical Rearrangement of 3-Hydroxyoxindoles into Benzoxazinones.

Authors:  Marie Vayer; Miryam Pastor; Christiane Kofink; Nuno Maulide
Journal:  Org Lett       Date:  2021-12-24       Impact factor: 6.005

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.